Key role of P38 mitogen-activated protein kinase and the lipoxygenase pathway in angiotensin II actions in H295R adrenocortical cells.
Angiotensin II (ANG II) can activate the mitogen-activated protein kinases (MAPKs) and stress-activated protein kinases in several cell types. We have previously shown that the 12-lipoxygenase (12-LO) pathway of arachidonic acid metabolism is a mediator of ANG II-induced aldosterone synthesis in adrenal glomerulosa cells. To evaluate the role of MAPK activation in ANG II and the effects of LO on aldosterone synthesis, experiments were performed using the human adrenocortical cell line H295R, which secretes aldosterone in response to ANG II. MAPK activities were determined by Western immunoblotting using specific antibodies to their activated phosphorylated forms. ANG II led to a dose-dependent increase in extracellular signal-regulated kinase (ERK1/2) activity in these cells, with a peak at 5 min and lasting up to 3 h. The effects of ANG II were blocked by the ANG-II Type 1 receptor antagonist losartan. A specific 12-LO product, 12(S)-hydroxyeicosatetraenoic acid (12-HETE), had no direct effect on ERK activity. However, both ANG II and 12-HETE led to significant dose-dependent increases in p38 MAPK activity with peak effects at 5 min. By contrast, the 15-LO product, 15-HETE, had no effect on p38 MAPK activity. Furthermore, two dissimilar 12-LO inhibitors, CDC and baicalein, blocked ANG II-induced p38 MAPK activation. ANG II significantly increased aldosterone release, and this effect was inhibited by the LO inhibitor baicalein, as well as a specific p38 MAPK inhibitor, SB202190, but not by PD098059, a specific inhibitor of the ERK activator MEK. In summary, in H295R cells, ANG II activated ERK and p38 MAPKs, ANG II-induced p38 MAPK was mediated by 12-LO activation, and ANG II-induced aldosterone synthesis was prevented by 12-LO- and p38 MAPK-specific inhibitors. These results suggest, for the first time, that activation of p38 MAPK, either directly or via LO activation, participates in aldosterone's stimulatory effects of ANG II in adrenal cells.
Natarajan
Rama
R
Gonda Diabetes and Genetics Research Center, Beckman Research Institute of the City of Hope, Duarte, CA, USA.
Yang
Dong-Chang
DC
Lanting
Linda
L
Nadler
Jerry L
JL
D019377:12-Hydroxy-5,8,10,14-eicosatetraenoic Acid / Q000494:pharmacology; D000302:Adrenal Cortex / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*; D000450:Aldosterone / Q000378:metabolism; D000804:Angiotensin II / Q000494:pharmacology*; D002460:Cell Line; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D048031:JNK Mitogen-Activated Protein Kinases; D008084:Lipoxygenase / Q000378:metabolism*; D016859:Lipoxygenase Inhibitors; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism / Q000502:physiology*; D048051:p38 Mitogen-Activated Protein Kinases
D004791:Enzyme Inhibitors; D016859:Lipoxygenase Inhibitors; D000804:Angiotensin II; D000450:Aldosterone; D019377:12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; D008084:Lipoxygenase; D048031:JNK Mitogen-Activated Protein Kinases; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases